1Panchaganula R, Thomas NS. Biopharmaceutics and pharmacokinetics in drug research[J]. Int J Pharm, 2000, 201(2): 131 - 150.
2Valler MJ, Green D. Diversity screening versus focussed screening in drug discovery[J]. Drug Discov Today, 2000,5(7) :286 - 293.
3Fox S, Farr-Jones S, Yund MA. High throughput screening for drug discovery: continually transitioning into new technology[J]. J Biomol Screen, 1999, 4(4): 183 - 186.
4Hertzberg RP, Pope AJ. High-throughput screening:new technology for the 21 st century [J]. Curr Opin Chem Biol,2000, 4(4) :445 - 451.
5Valentin-Severin I, Laignelet L, Lhuguenot JC, et al. Uridine uptake inhibition assay: an automated micromethod for the screening of cytotoxicity [J]. Toxicology, 2002, 171(2/3) :207 - 213.
6Offin P, Drake R. The select consortium[J]. J Assoc Lab Auto, 2000, 5(1):20-22.
7O' Brien J, Wilson L, Orton T, et al. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity[J]. Eur J Biochem, 2000,267(17) :5421 - 5426.
8Sundberg SA. High-throughput and ultra-high-throughput screening: solution- and cell-based approaches [J]. Curr Opin Biotechnol , 2000, 11(1):47- 53.
9Crouch SPM, Slater KJ. High-throughput cytotoxicity screening: hit and miss [J]. Drug Discov Today, 2001, 6(12) :48 - 53.
10Ashcroft RG, Lopez PA. Commercial high speed machines open new opportunities in high throughput flow cytometry (HTFC)[J]. J Immunol Methods, 2000, 243(1/2): 13 -24.
